Armistice Capital, LLC Increases Stake in Citius Oncology, Inc. to 9.99%

Armistice Capital, LLC and its managing member, Steven Boyd, have filed a Schedule 13G/A with the SEC, disclosing a significant increase in their position in Citius Oncology, Inc. (CTOR). As of March 31, 2026, the reporting persons beneficially own 9,299,917 shares of common stock, representing a 9.99% ownership stake in the company. This marks a substantial increase from their previously reported 0.0% position. The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC serves as the investment manager. Steven Boyd, as the managing member of Armistice Capital, may also be deemed to have shared voting and dispositive power over these securities. The filing indicates that the acquisition was made in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The transaction reached the 9.99% threshold, which is often a strategic limit to avoid certain regulatory implications while maintaining a major stake.